NHIA has released a draft practice standard that describes situations that may require the use of electronic mechanical pumps to minimize adverse reactions and promote adherence to infusion therapies administered in the home.
The National Home Infusion Foundation’s (NHIF) Status at Discharge Benchmarking initiative is based on the need for research that evaluates the safety of home infusion services and aims to understand why patients discontinue their home infusion service.
On Tuesday, September 19, 2023, the House Energy & Commerce Health Subcommittee held a legislative hearing, “Examining Policies to Improve Seniors’ Access to Innovative Drugs, Medical Devices, and Technology.” Home infusion was discussed at least 3 distinct times throughout the hearing, with a consensus that Medicare needs to improve beneficiary access to home infusion services.
NHIA submitted comments on a CMS PFS proposed rule (CMS-1784-P) that would affect Medicare classification and coverage of self-administered drugs, certain biologics and coding and billing requirements related to the use of single dose containers and drug waste.
NHIA responded to an FDA request for comment on “Increasing Patient Access to At-Home Use Medical Technologies,” applauding the agency for recognizing the importance of facilitating access to care in the home.
NHIA submitted comments to CMS on the proposed 2024 home health payment rule. CMS did not mention the HIT services benefit in its 2024 rulemaking, however, NHIA believes it is important to continue advocating on behalf of Medicare beneficiaries to improve access to home infusion services.
The Foundation has adopted the Poster Session at the NHIA Annual Conference as part of its efforts to advance NHIF’s mission of promoting investigator-initiated research related to home and alternate infusion. NHIF awards a $1000 scholarship to a poster that exemplifies an innovative approach to addressing current challenges in home infusion and has the possibility of further development.
Kassie Klasen, PharmD Fairview Pharmacy Services; Alicia Zagel, PhD, MPH Fairview Pharmacy Services; Mary Nelson, PharmD Fairview Pharmacy Services; Eric Betzold, MS Fairview Pharmacy Services; Brett Benfield, PharmD, MS, FNHIA Fairview Pharmacy Services
Health disparities have been exacerbated during the COVID-19 pandemic
Home infusion is a site of care (SOC) option for patients requiring intravenous (IV) or subcutaneous (SC) medications for treatment of acute and chronic medical conditions. Patients and payors have become aware of the sizeable cost savings associated with home infusion when compared to other SOC. There is a need to gain an understanding of the amount of savings associated with home infusion when compared to other SOCs such as the hospital. The literature review objective is to provide a critical evaluation of the current evidence of the cost savings associated with home and outpatient infusion therapy when compared to inpatient therapy.
On Friday June 30, 2023, CMS released proposed updates to the Medicare Home Health Prospective Payment System for CY 2024. The proposed home health rule does not address home infusion therapy (HIT) services other than to describe the potential interaction with the new Home IVIG Items and Service benefit, which replaces the IVIG demonstration starting on January 1, 2024.
The National Home Infusion Association (NHIA) applaudes the introduction of bipartisan legislation in the U.S. Senate that will ensure Medicare patients can receive the intravenous (IV) medications they need while at home.
The National Home Infusion Association (NHIA) is pleased to hold its second annual one-day Payor Summit. The event, designed to bring together representatives from commercial health insurance plans with home and specialty infusion leaders, will take place August 23, 2023 in Dallas, TX.
NHIA applauds the guidance issued by FDA to allow for decentralized clinical trials, including in patients’ homes. NHIA believes that allowing decentralized clinical trials will improve the representation in trials. According to the FDA guidance, “remote clinical trial visits and clinical trial-related activities are important strategies to make trials more convenient and more accessible” and “sponsors should strive for diversity and inclusiveness in trial populations.”
The National Home Infusion Association (NHIA) applauds the introduction of the “Expanding Care in the Home Act,” (H.R.2853) which would expand coverage for home-based services, such as home infusion, dialysis, diagnostic imaging, and personal care services for Medicare beneficiaries.
Amy Mulgrew, RN, CRNI, IgCN, VA-BC, Advanced Infusion Care; Ashley McKenna, RN, IgCN, Advanced Infusion Care; Erin Mullis, RN, IgCN, Advanced Infusion Care
A literature review was conducted to evaluate the comparative rate of effectiveness, treatment failure due to adverse event (ADE), patient satisfaction, antimicrobial stewardship concerns, and potential cost comparisons of daptomycin and vancomycin.
Daniel Decker, PharmD, MBA, BCACP, Option Care Health
A literature review was conducted to evaluate the comparative rate of effectiveness, treatment failure due to adverse event (ADE), patient satisfaction, antimicrobial stewardship concerns, and potential cost comparisons of daptomycin and vancomycin.
Rohae Musa, PharmD, Option Care Health; Maria Giannakos, PharmD, MBA, BCPS, BCSCP, Option Care Health; Suzanne Kluge, B.S. Pharm, MBA, RPh, BCSCP, FNHIA, Option Care Health
The study assessed the safety of natalizumab administration by comparing outcomes after receiving natalizumab infusions at home vs. infusion suites.
NHIA has released a draft practice standard that describes situations that may require the use of electronic mechanical pumps to minimize adverse reactions and promote adherence to infusion therapies administered in the home.
The National Home Infusion Foundation’s (NHIF) Status at Discharge Benchmarking initiative is based on the need for research that evaluates the safety of home infusion services and aims to understand why patients discontinue their home infusion service.
On Tuesday, September 19, 2023, the House Energy & Commerce Health Subcommittee held a legislative hearing, “Examining Policies to Improve Seniors’ Access to Innovative Drugs, Medical Devices, and Technology.” Home infusion was discussed at least 3 distinct times throughout the hearing, with a consensus that Medicare needs to improve beneficiary access to home infusion services.
NHIA submitted comments on a CMS PFS proposed rule (CMS-1784-P) that would affect Medicare classification and coverage of self-administered drugs, certain biologics and coding and billing requirements related to the use of single dose containers and drug waste.
NHIA responded to an FDA request for comment on “Increasing Patient Access to At-Home Use Medical Technologies,” applauding the agency for recognizing the importance of facilitating access to care in the home.
NHIA submitted comments to CMS on the proposed 2024 home health payment rule. CMS did not mention the HIT services benefit in its 2024 rulemaking, however, NHIA believes it is important to continue advocating on behalf of Medicare beneficiaries to improve access to home infusion services.
The Foundation has adopted the Poster Session at the NHIA Annual Conference as part of its efforts to advance NHIF’s mission of promoting investigator-initiated research related to home and alternate infusion. NHIF awards a $1000 scholarship to a poster that exemplifies an innovative approach to addressing current challenges in home infusion and has the possibility of further development.
Kassie Klasen, PharmD Fairview Pharmacy Services; Alicia Zagel, PhD, MPH Fairview Pharmacy Services; Mary Nelson, PharmD Fairview Pharmacy Services; Eric Betzold, MS Fairview Pharmacy Services; Brett Benfield, PharmD, MS, FNHIA Fairview Pharmacy Services
Health disparities have been exacerbated during the COVID-19 pandemic
Home infusion is a site of care (SOC) option for patients requiring intravenous (IV) or subcutaneous (SC) medications for treatment of acute and chronic medical conditions. Patients and payors have become aware of the sizeable cost savings associated with home infusion when compared to other SOC. There is a need to gain an understanding of the amount of savings associated with home infusion when compared to other SOCs such as the hospital. The literature review objective is to provide a critical evaluation of the current evidence of the cost savings associated with home and outpatient infusion therapy when compared to inpatient therapy.
On Friday June 30, 2023, CMS released proposed updates to the Medicare Home Health Prospective Payment System for CY 2024. The proposed home health rule does not address home infusion therapy (HIT) services other than to describe the potential interaction with the new Home IVIG Items and Service benefit, which replaces the IVIG demonstration starting on January 1, 2024.
The National Home Infusion Association (NHIA) applaudes the introduction of bipartisan legislation in the U.S. Senate that will ensure Medicare patients can receive the intravenous (IV) medications they need while at home.
The National Home Infusion Association (NHIA) is pleased to hold its second annual one-day Payor Summit. The event, designed to bring together representatives from commercial health insurance plans with home and specialty infusion leaders, will take place August 23, 2023 in Dallas, TX.
NHIA applauds the guidance issued by FDA to allow for decentralized clinical trials, including in patients’ homes. NHIA believes that allowing decentralized clinical trials will improve the representation in trials. According to the FDA guidance, “remote clinical trial visits and clinical trial-related activities are important strategies to make trials more convenient and more accessible” and “sponsors should strive for diversity and inclusiveness in trial populations.”
The National Home Infusion Association (NHIA) applauds the introduction of the “Expanding Care in the Home Act,” (H.R.2853) which would expand coverage for home-based services, such as home infusion, dialysis, diagnostic imaging, and personal care services for Medicare beneficiaries.
Amy Mulgrew, RN, CRNI, IgCN, VA-BC, Advanced Infusion Care; Ashley McKenna, RN, IgCN, Advanced Infusion Care; Erin Mullis, RN, IgCN, Advanced Infusion Care
A literature review was conducted to evaluate the comparative rate of effectiveness, treatment failure due to adverse event (ADE), patient satisfaction, antimicrobial stewardship concerns, and potential cost comparisons of daptomycin and vancomycin.
Daniel Decker, PharmD, MBA, BCACP, Option Care Health
A literature review was conducted to evaluate the comparative rate of effectiveness, treatment failure due to adverse event (ADE), patient satisfaction, antimicrobial stewardship concerns, and potential cost comparisons of daptomycin and vancomycin.
Rohae Musa, PharmD, Option Care Health; Maria Giannakos, PharmD, MBA, BCPS, BCSCP, Option Care Health; Suzanne Kluge, B.S. Pharm, MBA, RPh, BCSCP, FNHIA, Option Care Health
The study assessed the safety of natalizumab administration by comparing outcomes after receiving natalizumab infusions at home vs. infusion suites.
